ArticleFrontiers in immunology2022
Sex - a potential factor affecting immune checkpoint inhibitor therapy for cancers.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Androgen receptor may promote tumor progression via TTF-1/EGFR pathway in metastatic nasopharyngeal carcinoma.Translational oncology · 2026Article
- Early sex-related transcriptional differences in CD8Frontiers in immunology · 2026Article
- Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance.Cancers · 2025Article
- Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective study.BJC reports · 2025Article
- Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database.BMC cancer · 2025Article
- Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.Journal of clinical medicine · 2025Review
- Sex-specific differences in abscopal responses to combined radiotherapy and immune checkpoint inhibition-insights from a multicenter study.Frontiers in immunology · 2025Observational
- Decoding sex differences in human immunity through systems immunology.Oxford open immunology · 2025Review
- Risk Factors Predicting Outcomes in Advanced Upper Gastrointestinal Cancers Treated With Immune Checkpoint Inhibitors.Gastroenterology research · 2024Article
- Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy.Journal for immunotherapy of cancer · 2024Review
- Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer.Cancers · 2024Article
- An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.